	US 12,065,663 B2
	Vector and method for treating bietti's crystalline dystrophy
Liping Yang, Beijing (CN); Shaohong Chen, Beijing (CN); Ruixuan Jia, Beijing (CN); Fan Zhang, Beijing (CN); Saichao He, Beijing (CN); Tianyong Shi, Beijing (CN); Dandan Hao, Beijing (CN); Hongjie Pei, Beijing (CN); and Luying Zeng, Beijing (CN)
Assigned to CHIGENOVO CO., LTD, Beijing (CN)
Filed by CHIGENOVO CO., LTD, Beijing (CN)
Filed on Jul. 13, 2022, as Appl. No. 17/812,425.
Prior Publication US 2024/0018541 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/86 (2006.01); A61K 48/00 (2006.01); A61P 27/02 (2006.01); C12N 9/02 (2006.01)

CPC C12N 15/86 (2013.01) [A61P 27/02 (2018.01); C12N 9/0071 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01)]

9 Claims

1. A vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2; wherein the vector comprises the entire nucleotide sequence set forth in SEQ ID NO: 11; and wherein the vector is a recombinant AAV2/8 vector.

7. A method for treating or alleviating Bietti's crystalline dystrophy (BCD), comprising administrating the vector according to claim 1 to a subject in need thereof, wherein the administration is subretinal injection.